Ambler class |
Protein name |
PDB code |
Resolution (Å) |
Release date |
UniProt code |
PubMed ID |
DOI |
PDB |
Mutations |
Ligands |
Space group |
Unit cell parameters |
Z value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ▲ ▼ | ||||||||
B3 | SMB-1 | 3VPE | 1.60 | 2013-02-13 | G5ELM3 | 23070156 | 10.1128/AAC.01264-12 | pdb | ACT GOL SO4 ZN | P 31 | 67.829 67.829 48.670 ♦ 90.00 90.00 120.00 | 3 | |
B3 | SMB-1 | 3VQZ | 2.20 | 2013-02-13 | G5ELM3 | 23070156 | 10.1128/AAC.01264-12 | pdb | #MCR NA ZN | P 31 | 67.029 67.029 46.792 ♦ 90.00 90.00 120.00 | 3 | |
B3 | SMB-1 | 5AXO | 1.39 | 2016-05-11 | G5ELM3 | pdb | #LMP NA SO4 TRS ZN | P 1 | 36.900 41.170 45.320 ♦ 107.95 102.46 106.85 | 1 | |||
B3 | SMB-1 | 5AXR | 2.10 | 2016-05-11 | G5ELM3 | pdb | #COM NA ZN | P 31 | 67.112 67.112 46.717 ♦ 90.00 90.00 120.00 | 3 | |||
B3 | SMB-1 | 5AYA | 2.02 | 2016-05-11 | G5ELM3 | pdb | #X8Z NA SO4 ZN | P 31 | 68.097 68.097 49.110 ♦ 90.00 90.00 120.00 | 3 | |||
B3 | SMB-1 | 5B15 | 1.39 | 2016-05-11 | G5ELM3 | pdb | #DQM NA SO4 ZN | P 1 | 37.010 40.920 45.320 ♦ 107.57 102.56 107.01 | 1 | |||
B3 | SMB-1 | 5B1U | 1.57 | 2016-05-11 | G5ELM3 | pdb | #HIW NA SO4 ZN | P 1 | 37.030 41.460 45.440 ♦ 108.32 102.78 106.28 | 1 | |||
B3 | SMB-1 | 6K4T | 1.39 | 2019-08-07 | G5ELM3 | pdb | #JKE SO4 TRS ZN | P 1 | 37.040 41.590 45.550 ♦ 108.60 102.75 106.06 | 1 | |||
B3 | SMB-1 | 6K4X | 1.17 | 2019-08-07 | G5ELM3 | pdb | #D0U SO4 TRS ZN | P 1 | 36.997 41.682 45.660 ♦ 108.75 102.79 105.86 | 1 |
Statistics (number of structures): Overall (1663); class A (626); subclass B1 (403); subclass B2 (16); subclass B3 (104); class C (246); class D (268).
Last updated: November 20, 2024.
If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.
The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).
Contact: contact@bldb.eu